-
1
-
-
36348952607
-
Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents
-
DOI 10.1161/CIRCULATIONAHA.107.707331
-
Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007;116(21): 2391-2398. (Pubitemid 350145074)
-
(2007)
Circulation
, vol.116
, Issue.21
, pp. 2391-2398
-
-
Doyle, B.1
Rihal, C.S.2
O'Sullivan, C.J.3
Lennon, R.J.4
Wiste, H.J.5
Bell, M.6
Bresnahan, J.7
Holmes Jr., D.R.8
-
2
-
-
78651412362
-
Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: A systematic review and meta-analysis
-
Wiisanen ME, Abdel-Latif A, Mukherjee D, Ziada KM. Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2010;3(12):1262-1273.
-
(2010)
JACC Cardiovasc Interv
, vol.3
, Issue.12
, pp. 1262-1273
-
-
Wiisanen, M.E.1
Abdel-Latif, A.2
Mukherjee, D.3
Ziada, K.M.4
-
3
-
-
0037015262
-
Results of prevention of REStenosis with tranilast and its outcomes (PRESTO) trial
-
DOI 10.1161/01.CIR.0000028335.31300.DA
-
Holmes DR Jr, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002;106(10):1243-1250. (Pubitemid 34988643)
-
(2002)
Circulation
, vol.106
, Issue.10
, pp. 1243-1250
-
-
Holmes Jr., D.R.1
Savage, M.2
LaBlanche, J.-M.3
Grip, L.4
Serruys, P.W.5
Fitzgerald, P.6
Fischman, D.7
Goldberg, S.8
Brinker, J.A.9
Zeiher, A.M.10
Shapiro, L.M.11
Willerson, J.12
Davis, B.R.13
Ferguson, J.J.14
Popma, J.15
King III, S.B.16
Lincoff, A.M.17
Tcheng, J.E.18
Chan, R.19
Granett, J.R.20
Poland, M.21
more..
-
4
-
-
2942752021
-
Folate therapy and in-stent restenosis after coronary stenting
-
DOI 10.1056/NEJMoa032845
-
Lange H, Suryaprantata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004; 350(26):2673-2681. (Pubitemid 38788002)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.26
, pp. 2673-2681
-
-
Lange, H.1
Suryapranata, H.2
De Luca, G.3
Borner, C.4
Dille, J.5
Kallmayer, K.6
Pasalary, M.N.7
Scherer, E.8
Dambrink, J.-H.E.9
-
5
-
-
67650755016
-
Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies
-
Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009; 119(25):3198-3206.
-
(2009)
Circulation.
, vol.119
, Issue.25
, pp. 3198-3206
-
-
Kirtane, A.J.1
Gupta, A.2
Iyengar, S.3
-
6
-
-
77952948745
-
Long-term outcomes following coronary drug-eluting- and baremetal- stent implantation
-
Auer J, Leitner A, Berent R, Lamm G, Lassnig E, Krennmair G. Long-term outcomes following coronary drug-eluting- and baremetal- stent implantation. Atherosclerosis. 2010;210(2):503-509.
-
(2010)
Atherosclerosis
, vol.210
, Issue.2
, pp. 503-509
-
-
Auer, J.1
Leitner, A.2
Berent, R.3
Lamm, G.4
Lassnig, E.5
Krennmair, G.6
-
7
-
-
51749094385
-
Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention
-
Solinas E, Dangas G, Kirtane AJ, et al. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. Am J Cardiol. 2008;102(3):311-315.
-
(2008)
Am J Cardiol
, vol.102
, Issue.3
, pp. 311-315
-
-
Solinas, E.1
Dangas, G.2
Kirtane, A.J.3
-
8
-
-
33847167065
-
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study
-
DOI 10.1016/S0140-6736(07)60314-6, PII S0140673607603146
-
Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667-678. (Pubitemid 46281313)
-
(2007)
Lancet
, vol.369
, Issue.9562
, pp. 667-678
-
-
Daemen, J.1
Wenaweser, P.2
Tsuchida, K.3
Abrecht, L.4
Vaina, S.5
Morger, C.6
Kukreja, N.7
Juni, P.8
Sianos, G.9
Hellige, G.10
Van Domburg, R.T.11
Hess, O.M.12
Boersma, E.13
Meier, B.14
Windecker, S.15
Serruys, P.W.16
-
9
-
-
33847762819
-
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden
-
DOI 10.1056/NEJMoa067722
-
Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.N Engl J Med. 2007;356(10):1009-1019. (Pubitemid 46376801)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.10
, pp. 1009-1019
-
-
Lagerqvist, B.1
James, S.K.2
Stenestrand, U.3
Lindback, J.4
Nilsson, T.5
Wallentin, L.6
-
10
-
-
8344221349
-
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
-
Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109(25):3171-3175.
-
(2004)
Circulation
, vol.109
, Issue.25
, pp. 3171-3175
-
-
Matetzky, S.1
Shenkman, B.2
Guetta, V.3
-
11
-
-
51649108832
-
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty- Platelet Reactivity Predicts Outcome) study
-
Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty- Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008;52(14):1128-1133.
-
(2008)
J Am Coll Cardiol
, vol.52
, Issue.14
, pp. 1128-1133
-
-
Patti, G.1
Nusca, A.2
Mangiacapra, F.3
Gatto, L.4
D'Ambrosio, A.5
Di Sciascio, G.6
-
12
-
-
59849120163
-
Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up
-
Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119(2):237-242.
-
(2009)
Circulation.
, vol.119
, Issue.2
, pp. 237-242
-
-
Marcucci, R.1
Gori, A.M.2
Paniccia, R.3
-
13
-
-
0028070508
-
Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells
-
DOI 10.1016/0006-2952(94)90062-0
-
Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994;48(4):827-835. (Pubitemid 24283854)
-
(1994)
Biochemical Pharmacology
, vol.48
, Issue.4
, pp. 827-835
-
-
Pan, X.1
Arauz, E.2
Krzanowski, J.J.3
Fitzpatrick, D.F.4
Polson, J.B.5
-
14
-
-
20144384243
-
Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F
-
Kim MJ, Park KG, Lee KM, et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension. 2005;45(4):552-556.
-
(2005)
Hypertension
, vol.45
, Issue.4
, pp. 552-556
-
-
Kim, M.J.1
Park, K.G.2
Lee, K.M.3
-
15
-
-
78249237183
-
Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1/2 pathway
-
Yoo AR, Koh SH, Cho GW, Kim SH. Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1/2 pathway. J Atheroscler Thromb. 2010;17 (10):1009-1018.
-
(2010)
J Atheroscler Thromb
, vol.17
, Issue.10
, pp. 1009-1018
-
-
Yoo, A.R.1
Koh, S.H.2
Cho, G.W.3
Kim, S.H.4
-
16
-
-
0033529402
-
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty
-
Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100(1):21-26. (Pubitemid 29297935)
-
(1999)
Circulation
, vol.100
, Issue.1
, pp. 21-26
-
-
Tsuchikane, E.1
Fukuhara, A.2
Kobayashi, T.3
Kirino, M.4
Yamasaki, K.5
Kobayashi, T.6
Izumi, M.7
Otsuji, S.8
Tateyama, H.9
Sakurai, M.10
Awata, N.11
-
17
-
-
27844463244
-
Coronary stent restenosis in patients treated with cilostazol
-
DOI 10.1161/CIRCULATIONAHA.104.530097
-
Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005; 112(18):2826-2832. (Pubitemid 41641677)
-
(2005)
Circulation
, vol.112
, Issue.18
, pp. 2826-2832
-
-
Douglas Jr., J.S.1
Holmes Jr., D.R.2
Kereiakes, D.J.3
Grines, C.L.4
Block, E.5
Ghazzal, Z.M.B.6
Morris, D.C.7
Liberman, H.8
Parker, K.9
Jurkovitz, C.10
Murrah, N.11
Foster, J.12
Hyde, P.13
Mancini, G.B.J.14
Weintraub, W.S.15
-
18
-
-
0342955606
-
Effects of cilostazol on angiographic restenosis after coronary stent placement
-
Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86(5):499-503.
-
(2000)
Am J Cardiol
, vol.86
, Issue.5
, pp. 499-503
-
-
Park, S.W.1
Lee, C.W.2
Kim, H.S.3
-
19
-
-
34548633702
-
Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)
-
Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007;100(7): 1103-1108.
-
(2007)
Am J Cardiol
, vol.100
, Issue.7
, pp. 1103-1108
-
-
Lee, S.W.1
Park, S.W.2
Kim, Y.H.3
-
20
-
-
79952435293
-
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: Results from the DECLARELONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial
-
Lee SW, Park SW, Kim YH, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARELONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol. 2011;57(11):1264-1270.
-
(2011)
J Am Coll Cardiol.
, vol.57
, Issue.11
, pp. 1264-1270
-
-
Lee, S.W.1
Park, S.W.2
Kim, Y.H.3
-
21
-
-
78651287537
-
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy on ischemic complication after drugeluting stenT implantation) trial
-
Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drugeluting stenT implantation) trial. J Am Coll Cardiol. 2011;57(3): 280-289.
-
(2011)
J Am Coll Cardiol
, vol.57
, Issue.3
, pp. 280-289
-
-
Suh, J.W.1
Lee, S.P.2
Park, K.W.3
-
22
-
-
44349138210
-
Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
-
Biondi-Zoccai GG, Lotrionte M, Anselmino M, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J. 2008;155(6):1081-1089.
-
(2008)
Am Heart J.
, vol.155
, Issue.6
, pp. 1081-1089
-
-
Biondi-Zoccai, G.G.1
Lotrionte, M.2
Anselmino, M.3
-
23
-
-
67650935286
-
Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: An evidence-based approach to answering a clinical query
-
Singh I, Shafiq N, Pandhi P, et al. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol. 2009;68(1):4-13.
-
(2009)
Br J Clin Pharmacol
, vol.68
, Issue.1
, pp. 4-13
-
-
Singh, I.1
Shafiq, N.2
Pandhi, P.3
-
24
-
-
77955428270
-
Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: A meta-analysis
-
Jennings DL, Kalus JS. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol. 2010;50(4):415-421.
-
(2010)
J Clin Pharmacol
, vol.50
, Issue.4
, pp. 415-421
-
-
Jennings, D.L.1
Kalus, J.S.2
-
25
-
-
40749126089
-
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation in Diabetic Patients)
-
Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008;51(12):1181-1187.
-
(2008)
J Am Coll Cardiol
, vol.51
, Issue.12
, pp. 1181-1187
-
-
Lee, S.W.1
Park, S.W.2
Kim, Y.H.3
-
26
-
-
62949165644
-
Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study
-
Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157(4):733-739.
-
(2009)
Am Heart J
, vol.157
, Issue.4
, pp. 733-739
-
-
Han, Y.1
Li, Y.2
Wang, S.3
-
27
-
-
0037030658
-
Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization
-
Morice MC, Serruys PW, Sousa JE, et al. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346(23):1773-1780.
-
(2002)
N Engl J Med
, vol.346
, Issue.23
, pp. 1773-1780
-
-
Morice, M.C.1
Serruys, P.W.2
Sousa, J.E.3
-
28
-
-
0037422604
-
Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions
-
DOI 10.1161/01.CIR.0000047700.58683.A1
-
Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107(1):38-42. (Pubitemid 36070930)
-
(2003)
Circulation
, vol.107
, Issue.1
, pp. 38-42
-
-
Grube, E.1
Silber, S.2
Hauptmann, K.E.3
Mueller, R.4
Buellesfeld, L.5
Gerckens, U.6
Russell, M.E.7
-
29
-
-
0032968970
-
Cilostazol
-
DOI 10.2165/00002512-199914010-00005
-
Sorkin EM, Markham A. Cilostazol. Drugs Aging. 1999;14(1): 63-71. (Pubitemid 29050247)
-
(1999)
Drugs and Aging
, vol.14
, Issue.1
, pp. 63-71
-
-
Sorkin, E.M.1
Markham, A.2
-
30
-
-
0037114872
-
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication
-
DOI 10.1016/S0002-9149(02)02869-2, PII S0002914902028692
-
Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314-1319. (Pubitemid 35449476)
-
(2002)
American Journal of Cardiology
, vol.90
, Issue.12
, pp. 1314-1319
-
-
Thompson, P.D.1
Zimet, R.2
Forbes, W.P.3
Zhang, P.4
-
31
-
-
15244356877
-
Comparison of cilostazol and clopidogrel after successful coronary stenting
-
Lee SW, Park SW, Hong MK, et al. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol. 2005;95(7):859-862.
-
(2005)
Am J Cardiol.
, vol.95
, Issue.7
, pp. 859-862
-
-
Lee, S.W.1
Park, S.W.2
Hong, M.K.3
-
32
-
-
24644465504
-
Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent [3]
-
Wessely R, Kastrati A, Schömig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med. 2005;143(5):392-394. (Pubitemid 41266615)
-
(2005)
Annals of Internal Medicine
, vol.143
, Issue.5
, pp. 392-394
-
-
Wessely, R.1
Kastrati, A.2
Schomig, A.3
-
33
-
-
27644555633
-
Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis
-
Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005;46(10):1833-1837.
-
(2005)
J Am Coll Cardiol
, vol.46
, Issue.10
, pp. 1833-1837
-
-
Lee, S.W.1
Park, S.W.2
Hong, M.K.3
|